Aug 29, 2025 4:30 PM EDT Toronto, Ontario–(Newsfile Corp. – August 29, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 1,840,000 share purchase warrants (“Warrants“) expiring September 7th, 2025 to September 7th, 2028. The Warrants were issued on September 7th, 2023, pursuant to a private placement involving the issuance of 1,840,000 units of the Company. The Warrants are exercisable at $CAN 0.35 per share. All other terms and conditions of the Warrants will remain unchanged. The Warrant expiry date extension is subject to final acceptance by the TSX Venture Exchange. About Theralase® Technologies Inc. Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small … Read More

Toronto, Ontario–(Newsfile Corp. – August 26, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company’s unaudited condensed consolidated interim 2Q2025 financial statements (“Financial Statements“). Theralase® will be hosting a conference call on Wednesday, September 3rd at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal quarter ending June 30th, 2025. Questions are welcome. To ensure we have time to review and properly address them during the call, please send them in advance to mperraton@theralase.com. Zoom Meeting Link: https://us02web.zoom.us/j/87203480163Webinar ID: 872 0348 0163 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom An archived version will be available on the website following the conference call. Financial Summary:For the six-month period ended June 30th: To view an … Read More

Theralase® Technologies Inc. plans to extend the expiry date of 4,800,000 share purchase warrants from June 30, 2025, to June 30, 2028. The warrants, issued in 2023, remain exercisable at $0.35 per share under the same terms. The extension is subject to TSX Venture Exchange approval. Theralase® develops light- and drug-activated therapies targeting cancer, bacteria, and viruses.

Theralase® Technologies Inc. closed a $571,000 private placement, issuing 2,855,000 units at $0.20 each. Funds will support its Phase II bladder cancer trial, Rutherrin® development, and corporate needs. Each unit includes a share and a five-year warrant at $0.30. Insider participation totaled 669,700 units. The offering awaits TSX Venture Exchange approval.

Theralase® successfully completed its 2025 Annual General Meeting, sharing strategic plans for 2025–2026 focused on clinical advancements and commercialization. A recording of the presentation is available for shareholders.

Theralase® Technologies Inc. reminds shareholders of its Annual General and Special Meeting (AGSM) on June 11, 2025, at 4:30 pm ET in Toronto. Following the meeting, a virtual corporate presentation and Q&A session will be held at 5:15 pm ET via Zoom to discuss strategic objectives for 2025-2026. An archived recording will be available the next business day.

Theralase® reported Q1 2025 results showing lower revenue and increased R&D expenses, ongoing Study II enrollment with promising bladder cancer interim data, continued HSV treatment development, and plans for Rutherrin® clinical trials starting early 2026 targeting multiple cancers.

Theralase® will present preclinical data comparing radiation-activated Rutherrin® versus radiation alone at ASTRO 2025, highlighting tumor targeting, immune activation, and survival benefits; clinical trials for various cancers begin early 2026.

Theralase®’s Rutherrin® is 100x more effective than radiation alone in preclinical cancer models, showing tumor targeting, immune activation, and improved survival; Phase I/II clinical trials start early 2026 targeting multiple cancers.

Theralase advances Ruvidar® trials for bladder and other cancers, targeting NDA submissions by 2026, launching multiple Phase I/II studies, seeking US listing, and pursuing international partnerships for commercialization and research collaboration.